Charged, Connected, Covered: Autel Energy supports its partners by successfully deploying its MaxiChargers across the globe, accelerating global electrification and the clean energy transition
21.7.2023 07:38:00 EEST | Business Wire | Press release
Autel Energy, a leading provider of innovative electric vehicle (EV) charging solutions, is delighted to announce new deployments of its MaxiChargers spanning the globe, including North America, Europe, Asia-Pacific, Latin America and IMEA (India, Middle East and Africa).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230720858024/en/
Autel's new MaxiCharger deployments receive positive global feedback (Graphic: Business Wire)
Autel Energy deployed its state-of-the-art MaxiChargers through its partners in each of these regions. The MaxiChargers installed at partner sites include the AC Ultra and DC Fast, providing electric vehicle drivers with fast and reliable EV charging. These sites have provided valuable opportunities for customers to witness and experience Autel’s seamless charging process, connect with shared electric mobility goals, and benefit from Autel’s exemplary localized and global services.
“Indigo Energy has chosen to partner with Autel Energy because they offer a good current and future product lineup, and demonstrate professionalism. Their chargers provide a fantastic charging experience and have received highly positive feedback from customers. People love the bright, responsive screens as well as the very convenient cable length," said Colson Rivers, Account Executive at Indigo Energy, a notable energy product provider in the US.
Autel Energy's success stems from its dedication to creating the ultimate one-stop charging solution, accelerating global electrification and enabling a sustainable future. By designing and manufacturing cutting-edge technologies and second-to-none charging solutions, Autel provides the world with reliable EV charging infrastructure, and leads by example in how to develop complete charging solutions and in building a green future.
Furthermore, Autel Energy's commitment to delivering both local and global services highlights its dedication to meeting the unique needs of customers in each region. With strategically positioned service centers and a strong network of authorized partners, Autel guarantees rapid customer support and enables Autel to provide tailored solutions that align with local regulations, infrastructure requirements, and market demands.
The latest deployment of Autel's MaxiChargers enhances partners' confidence and charging experience, cementing its position as the preferred choice for EV charging operators globally. Autel's unwavering commitment to innovation, reliability, and customer satisfaction has enabled the company to gain the trust of customers and establish long-term partnerships worldwide.
“We are excited to announce our latest MaxiCharger deployments around the globe. Autel's dedication to localized service helps partners feel at ease, especially in after-sales service and maintenance. A commitment to reliable service allows for quick response times and on-site support,” said Kelvin Cao, Vice President at Autel Energy. "Through our partner sites, we have demonstrated our commitment to providing innovative and reliable charging solutions to customers around the world and helping partners achieve business success. We look forward to continuing to collaborate with them to shape the future of mobility, achieving more success in the years to come and accelerating the transition to clean energy. At Autel Energy, we've got you charged, connected, and covered."
As the electric vehicle market continues to experience rapid growth, Autel Energy remains at the forefront of the industry, poised to deliver cutting-edge charging solutions that revolutionize the future of mobility. With a relentless pursuit of excellence, Autel Energy is dedicated to shaping a cleaner and more sustainable world through advanced charging infrastructure.
Get your complete one-stop charging solution here: https://autelenergy.com/pages/become-a-partner.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720858024/en/
Contact information
Media Contact
Melody Yu
marketing@autel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom